Trial · NCT02212015
Results by group37
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 37
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Rate of Progression-free Survival | Pazopanib + Paclitaxel | 12 | Participants | ||
| Rate of Progression-free Survival, Subgroup 1 Analysis | Pazopanib + Paclitaxel | cutaneous angiosarcoma | 11 | Participants | |
| Rate of Progression-free Survival, Subgroup 1 Analysis | Pazopanib + Paclitaxel | visceral angiosarcoma | 1 | Participants | |
| Rate of Progression-free Survival, Subgroup 2 Analysis | Pazopanib + Paclitaxel | primary angiosarcoma | 6 | Participants | |
| Rate of Progression-free Survival, Subgroup 2 Analysis | Pazopanib + Paclitaxel | secondary angiosarcoma | 6 | Participants | |
| Overall Survival | Pazopanib + Paclitaxel | 21.6 | 95% Confidence Interval 20.5 to NA | months | |
| Overall Survival, Subgroup 1 Analysis | Pazopanib + Paclitaxel | cutaneous angiosarcoma | 21.6 | 95% Confidence Interval 10.0 to 21.6 | months |
| Overall Survival, Subgroup 1 Analysis | Pazopanib + Paclitaxel | visceral angiosaroma | 20.5 | 95% Confidence Interval 2.8 to NA | months |
| Overall Survival, Subgroup 2 Analysis | Pazopanib + Paclitaxel | primary angiosarcoma | 20.5 | 95% Confidence Interval 10.0 to NA | months |
| Overall Survival, Subgroup 2 Analysis | Pazopanib + Paclitaxel | secondary angiosarcoma | 21.6 | 95% Confidence Interval NA to NA | months |
| Response Rate (RR) | Pazopanib + Paclitaxel | CR | 2 | Participants | |
| Response Rate (RR) | Pazopanib + Paclitaxel | PR | 7 | Participants | |
| Response Rate (RR) | Pazopanib + Paclitaxel | SD | 6 | Participants | |
| Response Rate (RR) | Pazopanib + Paclitaxel | PD | 10 | Participants | |
| Response Rate (RR) | Pazopanib + Paclitaxel | NE | 1 | Participants | |
| Response Rate (RR), Subgroup1 Analysis | Pazopanib + Paclitaxel | cutaneous angiosarcoma / CR | 2 | Participants | |
| Response Rate (RR), Subgroup1 Analysis | Pazopanib + Paclitaxel | cutaneous angiosarcoma / PR | 6 | Participants | |
| Response Rate (RR), Subgroup1 Analysis | Pazopanib + Paclitaxel | cutaneous angiosarcoma / SD | 4 | Participants | |
| Response Rate (RR), Subgroup1 Analysis | Pazopanib + Paclitaxel | cutaneous angiosarcoma / PD | 6 | Participants | |
| Response Rate (RR), Subgroup1 Analysis | Pazopanib + Paclitaxel | cutaneous angiosarcoma / NE | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02212015/results